Repurposing functional inhibitors of acid sphingomyelinase (fiasmas): an opportunity against SARS‐CoV‐2 infection?
Open Access
- 1 March 2021
- journal article
- editorial
- Published by Wiley in Journal of Clinical Pharmacy and Therapeutics
- Vol. 46 (5) , 1213-1219
Abstract
What is known and objective Infection by SARS‐CoV‐2, the virus responsible of COVID‐19, is associated with limited treatment options. The purpose of this study was to evaluate the rationale for repurposing functional inhibitors of acid sphingomyelinase (FIASMAs), several of which are approved medicines, for the treatment of SAR‐CoV‐2 infections. Comment We propose and discuss the FIASMAs’ lysosomotropism as a possible explanation for their observed in vitro activities against viruses, and more specifically against infections caused by coronaviruses such as SARS‐CoV‐2. Successful in vitro‐to‐in vivo translation of FIASMAs requires that their pharmacokinetics (dosing regimen and drug‐drug interactions) are matched with viral kinetics. What is new and conclusion Drug repurposing to ensure rapid patient access to effective treatment has garnered much attention in this era of the COVID‐19 pandemic. The observed lysosomotropic activity of small‐molecule FIASMA compounds suggests that their repurposing as potential drugs against SARS‐CoV‐2 is promising.Keywords
This publication has 42 references indexed in Scilit:
- Functional Inhibitors of Acid Sphingomyelinase (FIASMAs)2013
- Virus Entry by EndocytosisAnnual Review of Biochemistry, 2010
- Functional Inhibitors of Acid Sphingomyelinase (FIASMAs): A Novel Pharmacological Group of Drugs with Broad Clinical ApplicationsCellular Physiology and Biochemistry, 2010
- Amiodarone Alters Late Endosomes and Inhibits SARS Coronavirus Infection at a Post-Endosomal LevelAmerican Journal of Respiratory Cell and Molecular Biology, 2008
- Is the anti-psychotic, 10-(3-(dimethylamino)propyl)phenothiazine (promazine), a potential drug with which to treat SARS infections?Antiviral Research, 2008
- Identification of New Functional Inhibitors of Acid Sphingomyelinase Using a Structure−Property−Activity Relation ModelJournal of Medicinal Chemistry, 2007
- Clathrin-Dependent Entry of Severe Acute Respiratory Syndrome Coronavirus into Target Cells Expressing ACE2 with the Cytoplasmic Tail DeletedJournal of Virology, 2007
- Murine Coronavirus Requires Lipid Rafts for Virus Entry and Cell-Cell Fusion but Not for Virus ReleaseJournal of Virology, 2005
- Old drugs as lead compounds for a new disease? Binding analysis of SARS coronavirus main proteinase with HIV, psychotic and parasite drugsBioorganic & Medicinal Chemistry, 2004
- Pharmacokinetics of chlorpromazine and key metabolitesEuropean Journal of Clinical Pharmacology, 1993